Shree Ganesh Remedies Ltd Q1 Profit Falls 67.5% to ₹1.12 Crore

Shree Ganesh Remedies Ltd reported consolidated net profit of ₹1.12 crore in the quarter ended June 30, 2026, down 67.5% from ₹3.45 crore a year earlier. Revenue from operations fell 41.8% year on year to ₹14.36 crore from ₹24.67 crore, while consolidated revenue was reported at ₹15.30 crore.

What were Shree Ganesh Remedies' Q1 FY27 results?

Shree Ganesh Remedies reported a substantial decline in both revenue and profitability for the June 2026 quarter. Consolidated revenue was ₹15.30 crore, representing a 55.3% fall quarter on quarter and a 39.6% decline year on year, according to the reported quarterly figures. Revenue from operations was ₹14.36 crore, down 42% year on year.

Consolidated profit after tax stood at ₹1.12 crore, compared with ₹3.45 crore in the corresponding quarter of the previous year. The company said net profit declined 82.1% quarter on quarter and 67.5% year on year. Earnings per share for the quarter was ₹0.87.

The board approved the unaudited standalone and consolidated results for the quarter ended June 30, 2026 at its meeting on August 12, 2026. The reported numbers followed a stronger March 2026 quarter, when sales were ₹33.20 crore and operating profit was ₹11.38 crore in the quarterly data provided.

How did the June quarter compare with recent performance?

The June quarter marked a sharp sequential reversal from the March 2026 period in the figures reported for Shree Ganesh Remedies. Sales declined to ₹14.36 crore in June 2026 from ₹33.20 crore in March 2026, while operating profit fell to ₹3.35 crore from ₹11.38 crore over the same comparison.

The available quarterly series also shows that sales had been volatile across the preceding year. Sales were ₹24.67 crore in June 2025, increased to ₹30.32 crore in September 2025, declined to ₹21.11 crore in December 2025, and recovered to ₹33.20 crore in March 2026 before falling in June 2026.

Operating profit margin was reported at 28.05% for the June 2026 quarter in the company news summary. The reported decline in revenue and profit means investors will assess the subsequent quarterly disclosure for information on whether the lower June-quarter base continued into the September period.

The financial result also contrasts with the September 2025 quarter, when Shree Ganesh Remedies reported net profit of ₹4.96 crore and sales of ₹30.32 crore. That quarter itself had recorded year-on-year declines, with profit down 22.62% and sales down 6.22% from September 2024.

What is Shree Ganesh Remedies considering at its October 31 board meeting?

Shree Ganesh Remedies has scheduled a board meeting for October 31, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The intimation was issued on October 27, 2026.

The company has closed its trading window from October 1, 2026 until 48 hours after the financial results are declared. The closure was stated to be in line with Securities and Exchange Board of India regulations and the company's code for prevention of insider trading.

The September-quarter results will be the next formal financial update after the June-quarter earnings. The board meeting notice does not provide financial estimates or guidance for the September quarter. It only specifies the results as the principal agenda item.

Separately, the board had appointed Vishal Thawani as scrutinizer for the company's 31st annual general meeting when it approved the June-quarter results. This appointment was part of the corporate actions disclosed alongside the August 12 board meeting outcome.

What do the AGM decisions indicate for shareholders?

Shree Ganesh Remedies held its 31st annual general meeting on September 12, 2026, through video conferencing. Shareholders adopted the audited standalone and consolidated financial statements for the year ended March 31, 2026, reappointed Chairman Chandulal Manubhai Kothia, ratified cost auditor remuneration, and approved the appointment of Hiral Ankitkumar Shah as an independent director.

All four resolutions were passed through electronic voting with 99.99% support in the disclosed voting results. Participation for the resolution adopting the FY26 financial statements was 79.10%, with 10,154,235 votes polled and 10,154,227 votes cast in favour.

For investors, the AGM outcomes address the company's routine financial statement, board, and audit-related governance decisions. They do not alter the June-quarter revenue and profit figures, but they confirm shareholder approval for the disclosed FY26 financial statements and governance actions.

The share price data associated with the AGM corporate action showed a last traded price of ₹522.65 on the announcement day and ₹659.20 on the record date of September 12, 2026. These data points are corporate-action reference prices and do not establish a direct cause for any price movement.

Conclusion

Shree Ganesh Remedies' June 2026 quarter was marked by lower revenue and a sharper fall in net profit. Revenue from operations declined 41.8% year on year to ₹14.36 crore, while consolidated profit after tax fell 67.5% to ₹1.12 crore and EPS stood at ₹0.87. The sequential drop from the March 2026 quarter was also evident in the reported sales and operating-profit figures.

The next disclosed event to watch is the October 31, 2026 board meeting, where Shree Ganesh Remedies will consider unaudited results for the September 2026 quarter and first half of the financial year. The company has already closed its trading window through 48 hours after the results announcement, as required under its insider-trading compliance framework.